14. April 2011

IFZ in den Medien,

SECA,

Venture Capital

Venture Capital investments in life sciences

Pedergnana Maurice

Prof. Dr. Maurice Pedergnana, General Secretary SECA

In the past decade this sector has emerged as the dominant investment field among innovative start-up firms both in numbers of transactions and in total amounts of investment. After the dot-com bubble burst in 2001 life sciences raced ahead of all other sectors in terms of venture capital investment. Its share has risen from about 20 % to over 70 % since 2004. Even in such a well developed entrepreneurial ecosystem as Switzerland’s life sciences have become the most important destination for venture capital.

Venture_Capital

In the past decade life sciences have emerged as the most important destination for early-stage investments in Switzerland. Since 1999 over CHF 3.1 billion of venture capital have reportedly

been invested in the areas of life sciences (of which 85 % or CHF 2.6 billion for biotechnology alone, i.e. without medtech). This amount by far exceeds the combined earlystage investments in other innovative sectors such as ICT, energy and environment, chemicals and materials, and others during this period.

Download the entire article here for further Information.

Find out more:
Explore the world of venture capial and corporate finance on www.seca.ch – the leading representive body for Switzerland’s private equity, venture capital and corporate finance industries

 

Kommentare

0 Kommentare

Kommentar verfassen

Danke für Ihren Kommentar, wir prüfen dies gerne.